Milligan M P, Moore D M, Singh M M, Buckingham M S, Elstein M
Curr Med Res Opin. 1978;5(9):734-8. doi: 10.1185/03007997809110214.
The clinical use of bromocriptine (2.5 mg twice daily) was investigated in 40 women attending an infertility clinic and presenting with secondary amenorrhoea (18) or with ovarian dysfunction (22) which had failed to respond to anti-oestrogen therapy. Patients in each group were sub-divided into those with raised and those with normal prolactin levels, and re-examined at 3 and 12 months after the start of treatment. The results confirmed that bromocriptine is effective in the treatment of hyperprolactinaemic states whether there is amenorrhoea or not. Moreover, in cases of ovarian dysfunction as well as of amenorrhoea where the prolactin levels were within the normal range, there was evidence to suggest that bromocriptine can be associated with a return of ovulation, although the mechanism by which it might do so still needs evaluation.
对40名前往不孕不育诊所就诊的女性进行了研究，她们患有继发性闭经（18例）或卵巢功能障碍（22例），且抗雌激素治疗无效，研究了溴隐亭（每日两次，每次2.5毫克）的临床应用。每组患者又分为泌乳素水平升高和正常的两组，并在治疗开始后的3个月和12个月进行复查。结果证实，无论有无闭经，溴隐亭对高泌乳素血症均有效。此外，在泌乳素水平正常的卵巢功能障碍和闭经病例中，有证据表明溴隐亭可能与排卵恢复有关，但其作用机制仍需评估。
